Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Aurora Cannabis Inc.NASDAQ: ACB

Capital Expenditures · Q4 FY2026 · quarter ended Mar 2026

Capital expenditures grows in line with its trailing trend

Q4 FY2026 capital expenditures of CA$5.19M (cash outflow) rose 20.5% year over year, ahead of the +19.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 13.2% from the prior quarter. Over 3 fiscal years it compounded at +23.0% a year.

Context

  • Capital expenditures amounted to 7.0% of revenue in FY2026, up 1.5 pp from a year earlier.
  • Capital expenditures grew in size in 3 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.5% holds above the trailing-twelve-month pace of +19.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$5.19M-13.2% QoQ
Last fiscal yearMar 2026
-CA$22.6M+19.9% YoY
LTMMar 2026
-CA$22.56M+19.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.5%——
1 year+19.9%——
3-year CAGR+23.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

CAD · from the cash flow

Latest · FY2026
(22.6M) CAD
Year-over-year change
-19.9%

Capital Expenditures vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.6% is the 2nd highest of 10, against a peer median of -41.0%.
  • Capital expenditures amounts to 7.3% of revenue for ACB, versus a peer median of 2.5%.
ACB Competitors
Capital Expenditures for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$22.56M CAD+19.6%+23.0%7.3%
OGIOrganigram Global Inc.LTM Mar 2026CA$11.4M CAD+2.4%—4.2%
HITIHigh Tide Inc.LTM Apr 2026CA$10.14M CAD-5.9%+5.5%1.5%
LFMDLifeMD, Inc.LTM Mar 2026$9.17M USD+175.1%-9.6%4.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$6.91M USD—-23.5%5.1%
CGCCanopy Growth CorporationLTM Mar 2026CA$6.66M CAD-41.0%-10.7%2.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$1.16M USD-4.6%-65.6%2.8%
EDITEditas Medicine, Inc.LTM Mar 2026$585K USD-91.7%-47.2%1.5%
BIOABioAge Labs, Inc.LTM Mar 2026$319K USD-59.7%+91.1%3.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81K USD-99.8%-43.2%1.0%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$3K USD-97.1%-37.0%0.0%
Peer median (excluding ACB) —-41.0%-23.5%2.5%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(57.08M)15.76M(58.77M)
Depreciation & Amortization93.66M43.57M32.78M22.55M14.23M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55.14K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.54M)10.21M(9.24M)
Accounts Receivables18.34M5.53M(4.5M)5.24M(8.17M)
Inventory21.07M49.03M3.87M(15.05M)65.93M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.06M)
Other Working Capital6.48M(71.61M)790K5.11M(58.93M)
Other Non-Cash Items1.45B190.11M(39.71M)(40.85M)40.18M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.55M)
Capital Expenditures(32.21M)(12.13M)(16.83M)(18.86M)(22.6M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments0000(52.35M)
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K14.02M(956K)235.61K
Investing Cash Flow(36.17M)(27.29M)(3.36M)(14.33M)(73.62M)
Debt Repayment(170.83M)—(85.37M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.92M820K9.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(475K)(131K)(154.4K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.79M
Effect of Forex Changes15.01M15.54M297K264K10.56M
Net Change in Cash16.35M(140.01M)(119.5M)1.83M(66.81M)
Free Cash Flow(142.48M)(127.95M)(85.34M)(2.85M)(36.15M)

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.